Skip to main content
. 2021 May 14;32(9):962–968. doi: 10.1097/CAD.0000000000001088

Table 3.

Tumor responses (N = 30)

Responses Toripalimab and doxorubicin
No %
CR 1 3.3
PR 10 33.3
SD 13 43.3
PD 6 20
ORR 11 36.7
DCR 24 80
Median PFS 8 months
PFR 3 months 80
PFR 6 months 63.3

CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; PFR, progression-free rate; PFS, progression-free survival; SD, stable disease.